Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

mithramycin A

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Plicamycin
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma.
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer’s Disease
Increasing evidence has shown that specificity protein 1 (Sp1) is abnormally increased in the brains of subjects with Alzheimer’s… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer
Cervical cancer is the third most common cancer and the third leading cause of death among women. However, the standard treatment… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Mithramycin A Inhibits Myeloid Cell Leukemia-1 to Induce Apoptosis in Oral Squamous Cell Carcinomas and Tumor Xenograft through Activation of Bax and Oligomerization
In several human malignancies, overexpression of myeloid cell leukemia-1 (Mcl-1) confers resistance to induction of apoptosis… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2013
Highly Cited
2013
Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts.
The transcription factor specificity protein 1 (Sp1) plays a role in the development and progression of various types of human… 
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2011
Highly Cited
2011
Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis.
Both betulinic acid (BA) and mithramycin A (MIT) exhibit potent antitumor activity through distinct mechanisms of Sp1 inhibition… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma
Mithramycin A (MitA) is a chemotherapeutic compound which has been used in the therapy of several types of cancer. For… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
Differential inhibition of restriction enzyme cleavage by chromophore-modified analogues of the antitumour antibiotics mithramycin and chromomycin reveals structure-activity relationships.
Differential cleavage at three restriction enzyme sites was used to determine the specific binding to DNA of the antitumour… 
Highly Cited
2007
Highly Cited
2007
Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer
Human pancreatic cancer over expresses the transcription factor Sp1. However, the role of Sp1 in pancreatic cancer angiogenesis… 
2007
2007
Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences
The antitumour antibiotic mithramycin A (MTA) is a DNA minor-groove binding ligand. It binds to C/G-rich tracts as a dimer that… 
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE